Other lawsuits allege that patients are not adequately warned of serious injuries associated with GLP-1 receptor agonists.[1][2] These drugs, such as Ozempic, Wegovy, Mounjaro or Saxenda, can cause complications such as gastroparesis requiring hospitalization, bowel obstruction, vision loss NAION, ileus, pancreatitis or aspiration during surgery.[1][2] Manufacturers Eli Lilly and Novo Nordisk face accusations that they concealed the risks of gastrointestinal disorders and failed to inform doctors and patients.[1][2] European authorities have noticed a sharp increase in counterfeit medicines with the substances semaglutide, liraglutide and tirsepatide, sold illegally via the web and social networks.[3] These unapproved preparations do not meet safety standards and may contain dangerous substances, which threaten serious health problems.[3][4] ŠÚKL warns that GLP-1 agonists require a prescription and must be taken under the supervision of a doctor, risks include nausea, vomiting or inflammation of the pancreas.[3][4] Buying from illegal sources promotes crime and endangers health.[3][4]